Bausch + Lomb Corp (BLCO)

Currency in USD
16.55
+0.34(+2.07%)
Closed·
16.55+0.01(+0.03%)
·
Earnings results expected in 14 days
BLCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.1716.73
52 wk Range
10.4517.86
Key Statistics
Prev. Close
16.21
Open
16.32
Day's Range
16.17-16.73
52 wk Range
10.45-17.86
Volume
413.76K
Average Volume (3m)
383.98K
1-Year Change
-5.4286%
Book Value / Share
18.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLCO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.54
Upside
+5.96%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Bausch + Lomb Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Neutral
Moving Averages
Strong Sell

Bausch + Lomb Corp Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corp SWOT Analysis


Eye Health Pionee
Bausch + Lomb leads in ophthalmology with strong revenue growth, facing challenges and opportunities in a competitive market landscape
Financial Resilience
Despite foreign exchange headwinds, B+L demonstrates ability to counteract tariffs and projects growth above end markets for 2025
Analyst Perspectives
Mixed analyst ratings with price targets ranging from $12 to $22, reflecting varied views on B+L's growth potential and market positioning
Strategic Focus
Explore B+L's emphasis on Dry Eye Disease portfolio and core segments as key drivers for future growth and market share expansion
Read full SWOT analysis

Bausch + Lomb Corp Earnings Call Summary for Q2/2025

  • Q2 2025 revenue up 3% YoY to $1.278B; Vision Care segment grew 6%
  • Full-year revenue guidance raised to $5.05-$5.15B; adjusted EBITDA guidance increased to $860-$910M
  • Invista implant recall managed effectively; 200,000 lenses shipped post-recall
  • Focus on growth and margin expansion; strong performance expected through 2026-2027
  • CEO highlights 'extraordinary opportunity'; CMO aims to 'change the standard of care'
Last Updated: 10/15/2025, 06:12 AM
Read Full Transcript

Compare BLCO to Peers and Sector

Metrics to compare
BLCO
Peers
Sector
Relationship
P/E Ratio
−19.2x−2.6x−0.6x
PEG Ratio
−1.10−0.270.00
Price/Book
0.9x1.5x2.6x
Price / LTM Sales
1.2x2.1x3.3x
Upside (Analyst Target)
3.5%44.8%45.0%
Fair Value Upside
Unlock29.2%6.5%Unlock

Analyst Ratings

5 Buy
9 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 17.54
(+5.96% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy21.00+26.89%19.00MaintainJan 27, 2026
Stifel
Hold14.00-15.41%-MaintainJan 15, 2026
Evercore ISI
Hold---DowngradeJan 05, 2026
Citi
Buy---UpgradeDec 11, 2025
Morgan Stanley
Buy21.00+26.89%14.00UpgradeDec 02, 2025

Earnings

Latest Release
Oct 29, 2025
EPS / Forecast
0.18 / 0.16
Revenue / Forecast
1.28B / 1.28B
EPS Revisions
Last 90 days

BLCO Income Statement

People Also Watch

102.44
UAN
-0.30%
16.390
SD
+2.18%
82.63
SWX
-0.37%
206.85
CAH
-5.11%
23.88
CVI
+2.31%

FAQ

What Is the Bausch + Lomb (BLCO) Stock Price Today?

The Bausch + Lomb stock price today is 16.55

What Stock Exchange Does Bausch + Lomb Trade On?

Bausch + Lomb is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Bausch + Lomb?

The stock symbol for Bausch + Lomb is "BLCO."

What Is the Bausch + Lomb Market Cap?

As of today, Bausch + Lomb market cap is 5.74B.

What Is Bausch + Lomb's Earnings Per Share (TTM)?

The Bausch + Lomb EPS (TTM) is -0.86.

When Is the Next Bausch + Lomb Earnings Date?

Bausch + Lomb will release its next earnings report on Feb 17, 2026.

From a Technical Analysis Perspective, Is BLCO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bausch + Lomb Stock Split?

Bausch + Lomb has split 0 times.

How Many Employees Does Bausch + Lomb Have?

Bausch + Lomb has 13500 employees.

What is the current trading status of Bausch + Lomb (BLCO)?

As of Feb 04, 2026, Bausch + Lomb (BLCO) is trading at a price of 16.55, with a previous close of 16.21. The stock has fluctuated within a day range of 16.17 to 16.73, while its 52-week range spans from 10.45 to 17.86.

What Is Bausch + Lomb (BLCO) Price Target According to Analysts?

The average 12-month price target for Bausch + Lomb is USD17.54, with a high estimate of USD21 and a low estimate of USD13. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +5.96% Upside potential.

What Is the BLCO After Hours Price?

BLCO's last after hours stock price is 16.55, the stock has decreased by 0.01, or 0.03%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.